S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanoma

Melanoma Research

Volumn 23, Issue 5, 2013, Pages 396-401

  Abusaif, Sail ^a   Jradi, Zeinab ^a   Held, Laura ^a   Pflugfelder, Annette ^a   Weide, Benjamin ^a   Meier, Friedegund ^a   Garbe, Claus ^a   Eigentler, Thomas K ^a  

^a Skin Cancer Program   (Germany)

Author keywords

Lactate dehydrogenase; Metastatic melanoma; Response Evaluation Criteria In Solid Tumors; S100B; Vemurafenib

Indexed keywords

LACTATE DEHYDROGENASE; PROTEIN S100B; TUMOR MARKER; VEMURAFENIB; ANTINEOPLASTIC AGENT; B RAF KINASE; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; S100B PROTEIN, HUMAN; SULFONAMIDE;

ACCURACY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; FEMALE; GOLD STANDARD; HUMAN; IMAGE ANALYSIS; MALE; MELANOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; BLOOD; ENZYMOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; SKIN NEOPLASMS; TIME; UPREGULATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; DISEASE PROGRESSION; FEMALE; HUMANS; INDOLES; L-LACTATE DEHYDROGENASE; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; S100 CALCIUM BINDING PROTEIN BETA SUBUNIT; SKIN NEOPLASMS; SULFONAMIDES; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; UP-REGULATION;

EID: 84887991814     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0b013e3283650741     Document Type: Article

References (21)

1. US Food and Drug Administration. FDA approves Zelboraf and companion diagnostic test for late-stage skin cancer, 17 August 2011.
2. F. Hoffmann-La Roche Ltd. Roche's Zelboraf receives EU approval for the treatment of people with deadly form of skin cancer, 20 February 2012.
3. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363:809-819.
4. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366:707-714.
5. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-2516.
6. Chapman PB, Hauschild A, Robert C, Larkin J, Haanen JB, Ribas A, et al. Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600Emutated melanoma. ASCO Annual Meeting, ASCO Annual Meeting Proceedings (Post-Meeting Edition), 30[8502], 20 May 2012.
7. Shumei M, Boyu K, Bing L, Xiaodong L. Biological effects of low dose radiation from computed tomography scanning. Int J Radiat Biol 2012; 89:326-333.
8. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247.
9. Reichenauer S. Luminometric measurement of protein S100 at malignant melanoma. University of Tuebingen, Medical Faculty, 11 July 2006.
10. R Development Core Team. R: A Language and Environment for Statistical Computing. [2.15.2]. Vienna: R Foundation for Statistical Computing; 2012.
11. Smit LH, Korse CM, Hart AA, Bonfrer JM, Haanen JB, Kerst JM, et al. Normal values of serum S-100B predict prolonged survival for stage IV melanoma patients. Eur J Cancer 2005; 41:386-392.
12. Weide B, Elsasser M, Buttner P, Pflugfelder A, Leiter U, Eigentler TK, et al. Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis. Br J Cancer 2012; 107:422-428.
13. Baudy AR, Dogan T, Flores-Mercado JE, Hoeflich KP, Su F, van BN, et al. FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973. EJNMMI Res 2012; 2:22.
14. Aisner DL, Maker A, Rosenberg SA, Berman DM. Loss of S100 antigenicity in metastatic melanoma. Hum Pathol 2005; 36:1016-1019.
15. Finck SJ, Giuliano AE, Morton DL. LDH and melanoma. Cancer 1983; 51:840-843.
16. Heimdal K, Hannisdal E, Gundersen S. Regression analyses of prognostic factors in metastatic malignant melanoma. Eur J Cancer Clin Oncol 1989; 25:1219-1223.
17. Sirott MN, Bajorin DF, Wong GY, Tao Y, Chapman PB, Templeton MA, et al. Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer 1993; 72:3091-3098.
18. Argenyi ZB, Cain C, Bromley C, Nguyen AV, Abraham AA, Kerschmann R, et al. S-100 protein-negative malignant melanoma: fact or fiction? A lightmicroscopic and immunohistochemical study. Am J Dermatopathol 1994; 16:233-240.
19. Gerlach R, Demel G, Konig HG, Gross U, Prehn JH, Raabe A, et al. Active secretion of S100B from astrocytes during metabolic stress. Neuroscience 2006; 141:1697-1701.
20. Schroeter ML, Steiner J. Elevated serum levels of the glial marker protein S100B are not specific for schizophrenia or mood disorders. Mol Psychiatry 2009; 14:235-237.
21. Ghanem G, Loir B, Morandini R, Sales F, Lienard D, Eggermont A, et al. On the release and half-life of S100B protein in the peripheral blood of melanoma patients. Int J Cancer 2001; 94:586-590.